Prenetics Global Limited Class A Ordinary Share (PRE)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns on capital, generate cash, and sell at a sensible price. Prenetics does not yet fit that picture. In fiscal Q2 2026, revenue was $46.5 million, but net income was -$9.0 million, a -19.32% net margin. For the trailing twelve months, free cash flow was -$37.2 million, giving a -12.5% FCF yield. FairStock's calculations at the 2026-10-13 close of $21.27 show a negative P/E of -6.15, a P/B of 3.95, ROE of -47.01%, and ROCE of -18.95%. Those are not the marks of a durable moat. The consumer health and genetic-testing brands, IM8 and CircleDNA, may have appeal, but negative margins and cash burn suggest little pricing power or scale advantage today. The balance sheet is a relative bright spot: debt-to-equity is 0.01 and Altman Z-Score is 3.64, so insolvency risk is not immediate. Yet Piotroski is only 4/9, and the Lynch category is none because there are only 0 year(s) of filed results, which tells me the track record is too short to judge. Revenue appears to be growing quickly in the latest quarter, but growth that produces losses and consumes cash is not yet valuable growth. At a $297.4 million market cap, the price already assumes a successful turnaround. I would want to see positive free cash flow and consistent profits before calling this cheap. Until then, it looks speculative and expensive versus its current numbers.

In plain English: Prenetics is a consumer health company selling products under IM8 and genetic testing through CircleDNA. The business looks weak today: in its latest quarter it had $46.5 million of sales but lost $9.0 million, and it is burning cash. At $21.27, the price looks expensive relative to its profits and net assets, even though it carries very little debt.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer